Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Steinberg - Jefferies Ken Cacciatore - Cowen David Amsellem - Piper Sandler Annabel Samimy - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals' Third Quarter 2021 Financial Results Conference Call [Operator Inst ...

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Peter Vozzo - Investor Relations Neil McFarlane - Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Chris Prentiss - Chief Financial Officer Adrian Quartel - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Ken Cacciatore - Cowen Marc Goodman - SVB Leerink David Amsellem - Piper Sandler Operator Greetings and welcome to the Adamas Pharmaceutical ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20- ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases May, 10 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements c ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases May, 10 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements c ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2021 were $19.3 million, including GOCOVRI product sales of $17.7 million, OSMOLEX ER product sales of $300,000, and royalty revenue from NAMZARIC of approximately $1.3 million [29] - GOCOVRI product sales increased by 22% year-over-year, primarily driven by volume growth [30] - R&D expenses for Q1 2021 were $1.8 million, down from $2.5 million in the prior year quarter [32] - SG&A expenses for Q1 2021 were $26.6 million, compared to $24.6 million in the prior year quarter [32] - Cash and investments as of March 31, 2021, were approximately $127.4 million [33] Business Line Data and Key Metrics Changes - GOCOVRI paid prescriptions grew 21% year-over-year to 8,735, with 7% sequential growth versus the prior quarter [18] - New prescriptions (NRx) for GOCOVRI increased by 18% year-over-year and 16% sequentially to a total of 590 NRx [18] - OSMOLEX ER was successfully integrated into the product portfolio, with existing patients receiving uninterrupted care [25] Market Data and Key Metrics Changes - The addressable population for GOCOVRI expanded from an estimated 200,000 to 400,000-500,000 with the approval of the OFF indication [24] - The pandemic negatively impacted the marketplace, evidenced by a 21% year-over-year decline in patient claims for levodopa/carbidopa [17] Company Strategy and Development Direction - The company aims to deepen engagement with stakeholders and expand its commercial footprint beyond Parkinson's disease [7][11] - A national disease education program called Picture More Time was launched to raise awareness of OFF episodes and dyskinesia [9] - The company plans to maintain a disciplined investment approach while focusing on GOCOVRI as a priority [27][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued growth of GOCOVRI and the positive early signs from the OFF indication launch [21][57] - The company is monitoring payer access and has achieved a 93% approval rate for GOCOVRI prescriptions [23][38] - Management acknowledged the fluidity of the operating environment due to the pandemic but noted an increase in live sales force interactions [20][48] Other Important Information - The company closed a $7.5 million settlement of patent litigation and raised approximately $66.5 million through public equity offerings [33] - Two new patents for ADS-4101 were issued, with plans to explore partnership opportunities rather than internal investment [13][36] Q&A Session Summary Question: Clarification on ADS-4101 product and business development - Management confirmed that ADS-4101 will not be developed internally and will seek partnership opportunities [36][37] Question: Insights on GOCOVRI payer rates and access - Management reported a 93% approval rate for GOCOVRI prescriptions, indicating improved access for patients [38] Question: Expectations for new prescriber growth and pushback on OFF indication - Management noted that education on comprehensive management of motor complications is necessary, and they are optimistic about early progress [42][43] Question: Impact of the pandemic on Q1 performance - Management acknowledged that the pandemic remained a headwind but noted an increase in live calls and access due to vaccinations [48] Question: Plans for OSMOLEX ER and promotional strategies - Management is cautiously expanding OSMOLEX ER's market presence while maintaining focus on GOCOVRI [51][63] Question: Future of the free trial program for GOCOVRI - The free trial program will continue as long as there is potential for growth in new prescribers and patients [62] Question: Feedback on marketing strategies for GOCOVRI and OSMOLEX ER - Management emphasized the importance of educating physicians on the distinct indications and patient groups for both products [68]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20 ...

| --- | --- | |------------------------------------------------------------------------------------------|-------| | | | | | | | Supernus Pharmaceuticals | | | © 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Corporate Overview April 2021 | | Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Sup ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases MARCH 2, 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20-2590184 | | ...